宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号

Core Viewpoint - The company, Xuantai Pharmaceutical (688247.SH), has received temporary approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Sitagliptin Metformin Extended-Release Tablets [1] Company Summary - The Sitagliptin Metformin Extended-Release Tablets were originally developed by Merck Sharp & Dohme and were approved for market in the U.S. in February 2012 [1] - The medication is indicated for improving blood sugar control in adults with type 2 diabetes [1]